Literature DB >> 2619511

Influence of harringtonine on human leukemia cell differentiation.

K Kuliczkowski1.   

Abstract

The influence of low doses of harringtonine (Ht) on differentiation of blood cells from acute myeloblastic (AML) and lymphoblastic leukemia (ALL) patients diagnosed according to FAB classification was tested. Out of five cases of ALL only in one case differentiation into mature lymphocytes appeared. In two cases out of four of AML differentiation was seen in one case into more mature granulocytic series and in another one into monocytes. Two out of 3 acute myelomonocytic leukemias (AMMOL) differentiated, one into more mature granulocyte cells and one into monocytes. One of our patients with AML (M2) in relapse was treated with ht using HOAP (harringtonine, oncovin, adriblastine, prednisone) schedule with good but transient effect. Prior to therapy in vitro tests performed with ht showed differentiation of leukemic cells into more mature granulocyte cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2619511

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  2 in total

1.  A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome.

Authors:  N Daver; A Vega-Ruiz; H M Kantarjian; Z Estrov; A Ferrajoli; S Kornblau; S Verstovsek; G Garcia-Manero; J E Cortes
Journal:  Eur J Cancer Care (Engl)       Date:  2013-05-23       Impact factor: 2.520

2.  A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia.

Authors:  V Lévy; S Zohar; C Bardin; A Vekhoff; D Chaoui; B Rio; O Legrand; S Sentenac; P Rousselot; E Raffoux; F Chast; S Chevret; J P Marie
Journal:  Br J Cancer       Date:  2006-07-18       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.